# EDGAR Filing Document

**Accession Number:** 0001783032
**File Stem:** 0001558370-23-003260
**Filing Date:** 2023-3
**Character Count:** 17914
**Document Hash:** d3f571ae6e0ca2a9c5b8cbe94e8e331d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-003260.hdr.sgml**: 20230309

**ACCESSION NUMBER**: 0001558370-23-003260

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230309

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230309

**DATE AS OF CHANGE**: 20230309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elevation Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001783032
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 841771427
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40523
- **FILM NUMBER:** 23718220

**BUSINESS ADDRESS:**
- **STREET 1:** 888 SEVENTH AVE
- **STREET 2:** 12TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10106
- **BUSINESS PHONE:** 212-651-6380

**MAIL ADDRESS:**
- **STREET 1:** 888 SEVENTH AVE
- **STREET 2:** 12TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10106

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 14ner Oncology, Inc.
- **DATE OF NAME CHANGE:** 20190719

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 9, 2023**

## Elevation Oncology, Inc.
**(Exact name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40523** | **84-1771427** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **888 Seventh Ave., 12th Floor**<br>**New York, New York** |  | **10106** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**(716) 371-1125**

**Registrant's Telephone Number, Including Area Code**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share | ELEV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02.&nbsp;&nbsp;&nbsp;&nbsp; Results of Operations and Financial Condition.**

On March 9, 2023, Elevation Oncology, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this report.

The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** **Exhibits** 

---

| | |
|:---|:---|
| **ExhibitNumber** | **Description of Document** |
| 99.1 | [Press release issued by Elevation Oncology, Inc. regarding its financial results for the fourth quarter and full year ended December 31, 2022, dated March 9, 2023.](elev-20230309xex99d1.htm) |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Elevation Oncology, Inc. | Elevation Oncology, Inc. |
| Date: March 9, 2023 | By: | /s/ Joseph J. Ferra, Jr. |
|  |  | Joseph J. Ferra, Jr. |
|  |  | *Interim Chief Executive Officer and President, and* <br>*Chief Financial Officer* |

---

## Exhibit 99.1

**Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results** 

● *Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023* 

● *Announced pipeline prioritization and realignment of resources focused on advancing EO-3021* 

● *Joseph Ferra, Chief Financial Officer, appointed Interim Chief Executive Officer* 

● *Cash runway extended into the fourth quarter of 2024* 

**NEW YORK, March 9, 2023** -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended December 31, 2022, and highlighted recent progress.

"Following the recently announced pipeline prioritization and realignment of resources, our clinical development strategy is focused on advancing EO-3021, a potential best-in-class antibody-drug conjugate targeting solid tumors expressing Claudin 18.2, and other pipeline programs to benefit patients with significant unmet medical needs," said Joseph Ferra, Interim Chief Executive Officer of Elevation Oncology. "We have cash runway into the fourth quarter of 2024 and expect to achieve multiple milestones during 2023, including the reporting of preclinical proof-of-concept data for EO-3021 during the first half of the year and the initiation of a U.S. Phase 1 clinical trial evaluating EO-3021 during the second half of the year."

**Recent Progress and Highlights**

*Corporate*

● **Announced pipeline prioritization and realignment of resources in January 2023.** As part of the announcement, the Company decided to prioritize key research and development efforts to advance EO-3021 and other pipeline programs including those through its existing partnership with Caris Life Sciences. The pipeline prioritization involved pausing further investment in the clinical development of seribantumab, and Elevation Oncology intends to pursue further clinical development of seribantumab only in collaboration with a partner. Further enrollment into the CRESTONE study has also paused, pending entering into a partnership. As part of the realignment of resources, the Company's workforce was reduced by approximately 30%.

● **Joseph Ferra appointed Interim Chief Executive Officer in January 2023.** The Company's Board of Directors appointed Mr. Ferra as Interim Chief Executive Officer. Mr. Ferra also remains as the Company's Chief Financial Officer.

*EO-3021*

● **Phase 1 clinical trial in the US to evaluate EO-3021 expected to initiate in the second half of 2023.** The Investigational New Drug application has been cleared with the U.S. Food and Drug Administration, and preparations are ongoing to initiate a Phase 1 clinical trial in the US. Elevation Oncology's partner, CSPC Pharmaceutical Group Limited (HKEX: 01093), is actively recruiting patients in the Phase I clinical trial of EO-3021 (SYSA1801) in China (NCT05009966).

● **Plan to present preclinical proof-of-concept data of EO-3021 at a major medical conference in the first half of 2023.** EO-3021 is a potential best-in-class, clinical-stage antibody-drug conjugate (ADC) designed to target Claudin 18.2 and selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Claudin 18.2 is a clinically validated oncology target expressed in several solid tumor types including many gastrointestinal cancers such as gastric, gastroesophageal junction and pancreatic cancer.

*Other Pipeline Programs*

● **Plan to present additional interim data of seribantumab from the CRESTONE study in the first half of 2023.** 

------

● **Continue research and development efforts to advance novel therapeutic drug candidates and targets**. Additional pipeline programs include those through its existing partnership with Caris Life Sciences.

**Expected Upcoming Milestones and Operational Objectives**

● Present preclinical proof-of-concept data of EO-3021 at a major medical meeting in the first half of 2023

● Initiate Phase 1 clinical trial of EO-3021 in the US in the second half of 2023

● Report additional interim data of seribantumab from the CRESTONE study in the first half of 2023

● Ongoing target evaluation for future pipeline expansion

**Fourth Quarter and Full Year 2022 Financial Results**

As of December 31, 2022, the Company had cash, cash equivalents and marketable securities totaling $90.3 million, compared to $107.9 million as of September 30, 2022.

Research and development expense for the fourth quarter 2022 was $14.5 million, compared to $6.2 million for the fourth quarter 2021. The increase in R&D expense was primarily related to seribantumab manufacturing and clinical trial expenses. For the year ended December 31, 2022, R&D expense was $78.7 million, compared to $23.6 million for the year ended December 31, 2021. The increase was primarily related to seribantumab manufacturing and clinical trial expenses and a one-time upfront license fee of $27.0 million paid to CSPC Megalith Biopharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, for the exclusive rights to develop and commercialize EO-3021 outside of Greater China.

General and administrative expense for the fourth quarter 2022 was $4.0 million, compared to $3.4 million for the fourth quarter 2021. The increase was primarily related to personnel costs. For the year ended December 31, 2022, G&A expense was $15.8 million, compared to $8.5 million for the year ended December 31, 2021. The increase was primarily related to personnel costs, professional services and other administrative costs.

Net loss for the fourth quarter 2022 was $19.0 million, compared to $9.6 million for the fourth quarter 2021.

**Financial Outlook**

Elevation Oncology expects its existing cash, cash equivalents and marketable securities as of December 31, 2022, will be sufficient to fund its current operations into the fourth quarter of 2024, without giving effect to financial covenant compliance under the Company's debt facility.

**About Elevation Oncology, Inc.**

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient's unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class, antibody-drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline. For more information, visit www.ElevationOncology.com.

**Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development

------

activities, expected timing of announcements of clinical results, potential benefits of Elevation Oncology's product candidates, potential opportunities to expand Elevation Oncology's product candidate pipeline, potential market opportunities for Elevation Oncology's product candidates, the ability of Elevation Oncology's product candidates to treat their targeted indications and Elevation Oncology's expectations about its cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "potential," "possible," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, the impact of the COVID-19 pandemic on Elevation Oncology's business, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

**Elevation Oncology Investor and Media Contact**

Candice Masse, 978-879-7273

Senior Director, Corporate Communications & Investor Relations

cmasse@elevationoncology.com

------

**Selected Financial Information**

**(In thousands, except share and per share data)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Year ended December 31,**  | **Year ended December 31,**  | **Three months ended December 31,**  | **Three months ended December 31,**  |
|  | **2022** | **2021** | **2022** | **2021** |
| **Statement of Operations items:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | $78717 | $23595 | $14502 | $6249 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 15832 | 8451 | 4035 | 3375 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 94549 | 32046 | 18537 | 9624 |
| Loss from operations | (94549) | (32046) | (18537) | (9624) |
| Other income (expenses), net | (506) | 7 | (480) | 2 |
| Loss before income taxes | (95055) | (32039) | (19017) | (9622) |
| Income tax expenses | 25 |  | 25 |  |
| Net loss | $(95080) | $(32039) | $(19042) | $(9622) |
| Net loss per share, basic and diluted | $(4.09) | $(2.64) | $(0.82) | $(0.41) |
| Weighted average common shares outstanding, basic and diluted | 23267120 | 12132610 | 23302066 | 23201971 |
| Comprehensive loss: |  |  |  |  |
| Net loss | $(95080) | $(32039) | $(19042) | $(9622) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive gain (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on marketable securities | (161) |  | 97 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive gain (loss) | $(161) | $— | $97 | $— |
| Total comprehensive loss | $(95241) | $(32039) | $(18945) | $(9622) |

---

------

**Selected Financial Information**

**(In thousands, except share and per share data)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **December 31,**  | **December 31,**  |
| **Selected Balance Sheet items:** | **2022** | **2021** |
| Cash, cash equivalents and marketable securities | $90280 | $146284 |
| Working capital<sup>1</sup> | 77285 | 140635 |
| Total assets | 94161 | 149494 |
| Long-term debt, net of discount | 29435 |  |
| Total stockholders' equity | 49032 | 140697 |

---

<sup>1</sup> We define working capital as current assets less current liabilities.

------